Last reviewed · How we verify

Nippon Shinyaku Co., Ltd. — Portfolio Competitive Intelligence Brief

Nippon Shinyaku Co., Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cytarabine Cytarabine marketed Antimetabolite DNA polymerase Oncology 1969-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
  2. Bristol-Myers Squibb · 1 shared drug class
  3. Centre Oscar Lambret · 1 shared drug class
  4. EMD Serono Research & Development Institute, Inc. · 1 shared drug class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
  6. Grupo Espanol Multidisciplinario del Cancer Digestivo · 1 shared drug class
  7. Hoffmann-La Roche · 1 shared drug class
  8. Asan Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nippon Shinyaku Co., Ltd.:

Cite this brief

Drug Landscape (2026). Nippon Shinyaku Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nippon-shinyaku-co-ltd. Accessed 2026-05-16.

Related